STOCK TITAN

AlloVir Inc - ALVR STOCK NEWS

Welcome to our dedicated news page for AlloVir (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on AlloVir.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AlloVir's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AlloVir's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.14%
Tags
conferences
-
Rhea-AI Summary
AlloVir presents positive long-term data from Phase 2 study of posoleucel for preventing viral infections in high-risk allo-HCT patients. The data shows low rates of clinically significant infections, end-organ disease, and 0% non-relapse mortality. Phase 3 trials are progressing with data readouts expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
conferences
AlloVir Inc

Nasdaq:ALVR

ALVR Rankings

ALVR Stock Data

84.42M
38.30M
48.95%
46.26%
5.49%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Waltham

About ALVR

allovir, inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific t cell (vst) therapies to prevent and treat devastating viral-associated diseases. the company's lead product is viralym-m, an allogeneic, off-the-shelf vst therapy, to treat bk virus, cytomegalovirus, adenovirus, epstein-barr virus, and human herpesvirus 6. its preclinical and clinical development product candidates include alvr106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; alvr109 to treat sars-cov-2 and covid-19; alvr107 for treating hepatitis b; and alvr108 to treat human herpesvirus-8, including kaposi's sarcoma, primary effusion lymphoma, and multicentric castleman's diseases. the company was formerly known as viracyte, inc. and changed its name to allovir, inc. in may 2019. allovir, inc. was founded in 2013 and is based in cambridge, massachusetts.